Last reviewed · How we verify
NCT06646887: PFA Champion
Comparison of Different Electroporation Systems in the Ablation Treatment of Atrial Fibrillation
NA trial testing Electroporation in AF in 150 participants. Participants enrolled and being followed up; not accepting new ones.
10 April 2025
Quick facts
| Lead sponsor | University Hospital Dubrava |
|---|---|
| Phase | NA |
| Status | Active, enrolled |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 150 |
| Start date | 15 October 2024 |
| Primary completion | 10 April 2025 |
| Estimated completion | 1 May 2025 |
| Sites | 2 locations across Croatia |
Drugs / interventions tested
- Electroporation
Conditions studied
- AF — all drugs for AF →
- Ablation of Atrial Fibrillation — all drugs for Ablation of Atrial Fibrillation →
Sponsor
University Hospital Dubrava
Who can join
Adults 18 to 85, any sex, with AF or Ablation of Atrial Fibrillation. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The participant is invited to participate in a clinical study comparing three different techniques for treating atrial fibrillation (AF) called electroporation systems. Atrial fibrillation is an irregular heartbeat that can cause complications if left untreated. The goal of this study is to determine which electroporation system is the most effective and safest for treating AF. These systems work by using electrical energy to disrupt abnormal heart tissue, helping to restore a normal heart rhythm.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT06646887
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Electroporation
Trials testing the same drug.
- NCT03603808 — VGX-3100 and Electroporation in Treating Patients With HIV-Positive High-Grade Anal Lesions · Phase 2 · completed
Other University Hospital Dubrava trials
Trials by the same sponsor.
- NCT07506304 — Biological Potentials in Arthroscopic All-inside Semitendinosus Anterior Cruciate Ligament Reconstruction · NA · not yet recruiting
- NCT07389434 — Feasibility, Safety, Cost-effectiveness, and Environmental Impact of Reprocessed Ablation Catheters in PVI · NA · recruiting
- NCT07339449 — Intraoperative Multimodal Monitoring as a Means in Reducing the Duration of Mechanical Ventilation in High-Risk Patients · NA · recruiting
- NCT06969586 — The Effect of Topical Rho-kinase Inhibitors on Corneas of Patients With Fuchs Endothelial Corneal Dystrophy · enrolling by invitation
- NCT06960629 — The Effect of ROCK Inhibitors on Corneas of Patients With Glaucoma and Pseudophakic Bullous Keratopathy (PBK) · enrolling by invitation
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06646887 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by University Hospital Dubrava
- Last refreshed: 1 April 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06646887.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing